Immune Response Settles Shareholder Suits
In the federal case, which is still subject to court approval, Immune Response agreed to pay the affected shareholders $9.6 million. Meanwhile, in the related case before the California state courts, the pharmaceutical company agreed to pay $250,000 and adopt certain corporate governance requirements.
A settlement approval hearing on the state case...
To view the full article, register now.